Drug Trial Radar · NCT07903493
Phase Ia Study of MST-931 in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Mabsoft Therapeutics (Australia) Pty. Ltd.; Mabsoft Therapeutics (Guangdong Hengqin) Co., Ltd.
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1a, randomized, double-blind study of MST-931 in healthy participants. The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous dose of MST-931 given to healthy participants. MST-931 is a monoclonal antibody.
Conditions
- Ankylosing Spondylitis (AS)
Interventions
MST-931Biological
MST-931 is a proprietary monoclonal antibody developed by Mabsoft Therapeutics.
MST-931 PlaceboBiological
Matching placebo for MST-931
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug related adverse events (AEs)Time frame: Through study completion, up to 113 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd
Herston, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.